AU2023216654B2 - Processes for the preparation of selective estrogen receptor degraders - Google Patents

Processes for the preparation of selective estrogen receptor degraders

Info

Publication number
AU2023216654B2
AU2023216654B2 AU2023216654A AU2023216654A AU2023216654B2 AU 2023216654 B2 AU2023216654 B2 AU 2023216654B2 AU 2023216654 A AU2023216654 A AU 2023216654A AU 2023216654 A AU2023216654 A AU 2023216654A AU 2023216654 B2 AU2023216654 B2 AU 2023216654B2
Authority
AU
Australia
Prior art keywords
compound
salt
formula
phenyl
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2023216654A
Other languages
English (en)
Other versions
AU2023216654A1 (en
Inventor
Alonso Jose ARGUELLES DELGADO
Boris Arnoldovich Czeskis
Mai Khanh Nguyen Hawk
Douglas Patton Kjell
Yu Lu
Nicholas Andrew Magnus
David Michael Remick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2023216654A1 publication Critical patent/AU2023216654A1/en
Priority to AU2025234145A priority Critical patent/AU2025234145A1/en
Application granted granted Critical
Publication of AU2023216654B2 publication Critical patent/AU2023216654B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
AU2023216654A 2022-02-01 2023-01-27 Processes for the preparation of selective estrogen receptor degraders Active AU2023216654B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025234145A AU2025234145A1 (en) 2022-02-01 2025-09-16 Processes for the preparation of selective estrogen receptor degraders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263305520P 2022-02-01 2022-02-01
US63/305,520 2022-02-01
US202263409060P 2022-09-22 2022-09-22
US63/409,060 2022-09-22
PCT/US2023/011671 WO2023150056A1 (en) 2022-02-01 2023-01-27 Processes for the preparation of selective estrogen receptor degraders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025234145A Division AU2025234145A1 (en) 2022-02-01 2025-09-16 Processes for the preparation of selective estrogen receptor degraders

Publications (2)

Publication Number Publication Date
AU2023216654A1 AU2023216654A1 (en) 2024-07-11
AU2023216654B2 true AU2023216654B2 (en) 2025-09-25

Family

ID=85382684

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2023216654A Active AU2023216654B2 (en) 2022-02-01 2023-01-27 Processes for the preparation of selective estrogen receptor degraders
AU2025234145A Pending AU2025234145A1 (en) 2022-02-01 2025-09-16 Processes for the preparation of selective estrogen receptor degraders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025234145A Pending AU2025234145A1 (en) 2022-02-01 2025-09-16 Processes for the preparation of selective estrogen receptor degraders

Country Status (15)

Country Link
US (1) US11926634B2 (https=)
EP (1) EP4472982A1 (https=)
JP (3) JP7387926B2 (https=)
KR (2) KR20250006312A (https=)
AU (2) AU2023216654B2 (https=)
CA (1) CA3243621A1 (https=)
CO (1) CO2024009411A2 (https=)
CR (1) CR20240283A (https=)
DO (1) DOP2024000150A (https=)
IL (1) IL313886A (https=)
JO (1) JOP20240169A1 (https=)
MX (1) MX2024009453A (https=)
PE (1) PE20241731A1 (https=)
TW (2) TW202523669A (https=)
WO (1) WO2023150056A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020137965A (ja) * 2019-03-01 2020-09-03 株式会社三洋物産 遊技機
US20240199629A1 (en) * 2022-02-01 2024-06-20 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654866B2 (en) * 2018-07-12 2020-05-19 Eli Lilly And Company Selective estrogen receptor degraders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100849559B1 (ko) 2004-01-22 2008-07-31 일라이 릴리 앤드 캄파니 혈관운동 증상의 치료를 위한 선택적 에스트로겐 수용체조절제
US20080221163A1 (en) 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
AU2012257802A1 (en) 2011-05-17 2013-10-31 F. Hoffmann-La Roche Ag Inhibitors of Bruton's tyrosine kinase
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
CN112424205B (zh) 2018-07-12 2023-10-31 伊莱利利公司 选择性的雌激素受体降解剂
KR20220046586A (ko) 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제
CA3169679A1 (en) 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2021191378A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
TWI837605B (zh) 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TWI894443B (zh) 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654866B2 (en) * 2018-07-12 2020-05-19 Eli Lilly And Company Selective estrogen receptor degraders

Also Published As

Publication number Publication date
CO2024009411A2 (es) 2024-07-29
KR20240135862A (ko) 2024-09-12
US20230242545A1 (en) 2023-08-03
MX2024009453A (es) 2024-08-09
JP2025183283A (ja) 2025-12-16
AU2023216654A1 (en) 2024-07-11
CR20240283A (es) 2024-09-03
AU2025234145A1 (en) 2025-10-02
US11926634B2 (en) 2024-03-12
DOP2024000150A (es) 2024-08-30
IL313886A (en) 2024-08-01
WO2023150056A1 (en) 2023-08-10
TW202346300A (zh) 2023-12-01
JP7387926B2 (ja) 2023-11-28
KR102743629B1 (ko) 2024-12-17
CA3243621A1 (en) 2023-08-10
KR20250006312A (ko) 2025-01-10
JP2023112696A (ja) 2023-08-14
TWI863110B (zh) 2024-11-21
JOP20240169A1 (ar) 2024-07-30
PE20241731A1 (es) 2024-08-19
JP7805336B2 (ja) 2026-01-23
TW202523669A (zh) 2025-06-16
JP2023162334A (ja) 2023-11-08
EP4472982A1 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
US8354528B2 (en) Process for making thienopyrimidine compounds
AU2025234145A1 (en) Processes for the preparation of selective estrogen receptor degraders
EP2844647B1 (en) Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
CN110041333B (zh) 溴结构域抑制剂化合物及其用途
JP2022513934A (ja) 置換複素環縮合γ－カルボリンの合成
JP7347852B2 (ja) 重水素化大環状化合物の調製方法
CN107548393B (zh) 适用于治疗癌症的1-(环)烷基吡啶-2-酮的三环稠合衍生物
CN118108669A (zh) 用于制备egfr抑制剂的中间体及其制备方法
CN117677616A (zh) 制备血红蛋白调节剂的方法
US20240199629A1 (en) Processes for the preparation of selective estrogen receptor degraders
BR112024013443B1 (pt) Processos para a preparação de degradadores seletivos de receptores de estrogênio
CN118647619A (zh) 选择性雌激素受体降解剂的制备方法
BR122025017409A2 (pt) Compostos degradadores seletivos de receptores de estrogênio
BR122025017416A2 (pt) Compostos degradadores seletivos de receptores de estrogênio
JP5711669B2 (ja) スピロケタール誘導体の製造方法
EP3303329B1 (en) Processes to make indazole derivatives
TW202527939A (zh) 單一的軸向不對稱化合物之選擇性製造方法
CN118271351A (zh) 一种2-羟基-4-三氟甲基苯硼酸的制备方法
HK1203964B (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)